UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) March 23, 2017

 

STELLAR BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   000-54598   N/A
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

  

332 E. Scott Street

Port Hueneme, California 93041

 (Address of principal executive offices) (Zip Code)

 

(805) 488-2800

(Registrant’s telephone number, including area code)

  

Not applicable.

(Former name or former address, if changed since last report)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(e)

 

On March 23, 2017, Stellar Biotechnologies, Inc. (the “Company”) held its 2017 annual general meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders approved the Company’s 2017 Incentive Compensation Plan. A description of the material terms and conditions of the 2017 Incentive Compensation Plan appears on pages 35-45 of the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on February 1, 2017 and such description is incorporated herein by reference. This summary is qualified in its entirety by the full text of the 2017 Incentive Compensation Plan, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 5.07.Submission of Matters to a Vote of Security Holders.

 

Set forth below are the matters submitted to the shareholders at the Annual Meeting, all of which were approved:

 

·the election of seven (7) directors to serve on the Company’s Board of Directors until the Company’s annual general meeting of shareholders to be held in 2018 or until their successors are duly elected and qualified;

 

·the ratification of the appointment of Moss Adams LLP as the Company’s auditors and independent registered public accounting firm for the fiscal year ending September 30, 2017; and

 

·the approval of the Company’s 2017 Incentive Compensation Plan.

 

The final voting results with respect to each matter are set forth below.

 

Election of Directors

 

NOMINEE FOR VOTES WITHHELD VOTES ABSTAIN BROKER NON-VOTES
Tessie M. Che 1,402,807 0 216,655 3,300,035
Paul Chun 1,401,459 0 218,003 3,300,035
David L. Hill 1,564,896 0 54,566 3,300,035
Daniel E. Morse 1,537,645 0 81,817 3,300,035
Frank R. Oakes 1,565,743 0 53,719 3,300,035
Charles V. Olson 1,406,768 0 212,694 3,300,035
Mayank D. Sampat 1,401,681 0 217,781 3,300,035

 

Ratification of the Appointment of Moss Adams LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Fiscal Year Ending September 30, 2017

 

FOR VOTES WITHHELD VOTES ABSTAIN BROKER NON-VOTES
4,840,165 0 79,332 0

 

Approval of 2017 Incentive Compensation Plan

 

FOR VOTES AGAINST VOTES ABSTAIN BROKER NON-VOTES
1,311,522 307,940 0 3,300,035

 

 

 

 

Item 8.01.Other Events.

 

Effective March 23, 2017, the Board approved the following Chairpersons and members of each of its standing committees:

 

    Nominating and Corporate
Audit Committee Compensation Committee Governance Committee
     
Mayank D. Sampat, Chair David L. Hill, Chair Paul Chun, Chair   
David L. Hill Mayank D. Sampat David L. Hill
Paul Chun Daniel E. Morse Mayank D. Sampat
  Paul Chun  
  Charles V. Olson  

 

Item 9.01.Financial Statements and Exhibits.

 

(d)       Exhibits.

 

Exhibit No.   Description
10.1   2017 Incentive Compensation Plan.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Stellar Biotechnologies, Inc.  
       
Date: March 28, 2017 By: /s/ Kathi Niffenegger  
    Name:  Kathi Niffenegger  
    Title:    Chief Financial Officer  

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
10.1   2017 Incentive Compensation Plan